...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Why now?

In the buyout scenario, this better not be the case as my CUSIP # on the shares is the same and I better be entitled to a payout.  I have held these shares since the split from RVX and only recently did I see it trade with a value.  I remain holding until a buyout scenario (which is hopefully soon).

Share
New Message
Please login to post a reply